ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

In a tight economy, disciplined cost management is often a better path than absorbing margin pressures or passing costs to ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

Researchers from Australia have developed a groundbreaking mRNA vaccine against tuberculosis (TB), showing promising results in pre-clinical mouse trials. This innovative vaccine could outperform the ...

Coding assistance and completion tools saved developers around 4 million hours last year, the retailer said during an ...

A beverage company thinks like a startup to maintain a closer connection with its customers. That’s the word from a recent episode of MIT’s and BCG’s Me, Myself, and AI, which featured Ronald den ...

The authorization was granted to ImmunityBio, the manufacturer of Anktiva ® (nogapendekin alfa inbakicept-pmln), an interleukin-15 receptor agonist, indicated with BCG for adult patients with BCG ...